Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing

The genomic landscape of prostate cancer can be established by non-invasive means from plasma DNA. Our approach provides specific genomic signatures within 2 days which may therefore serve as 'liquid biopsy'.